Enrofloxacin and its major metabolite ciprofloxacin in green sea turtles (Chelonia mydas): An explorative pharmacokinetic study

• DOI: 10.1111/jvp.12922
• Publication Date: 2020-10-27T03:11:34Z
• Authors: Saranya Poapolathep; Thanaphan Chomcheun; Mario Giorgi; Suthep Jualaong; Narumol Klangkaew; Napasorn Phaochoosak; Pareeya Udomkusonsri; Pedro Marin; Amnart Poapolathep
• Keywords: Dose

The present study aimed to assess the pharmacokinetic features of enrofloxacin (ENR) and its major metabolite, ciprofloxacin (CIP) in green sea turtles (Chelonia mydas) after single intravenous (i.v.) intramuscular (i.m.) administration at two dosages 5 7.5 mg/kg body weight (b.w.). used 10 animals randomly divided into equal groups. Blood samples were collected assigned times up 168 hr. concentrations ENR CIP turtle plasma quantified by a validated high-performance liquid chromatography equipped with fluorescence detector (HPLC-FLD). concentration experimental respect time was pharmacokinetically analyzed using noncompartment model. 144 hr i.v. i.m. administrations b.w., whereas 96 hr, respectively. elimination half-life values 38.7 50.4 dose rates b.w. administration, 33.6 22.6 maximum (Cmax ) 2.07 2.59 μg/ml value area under curve from 0 24 (AUC0-24 )/minimum inhibitory (MIC) ratio >125 for bacteria MIC 0.12 0.13 Based on data, susceptibility break-point (PK)/pharmacodynamic (PD) indices, dosage might be clinically appropriate treatment susceptible mydas).